Arnica Montana Whole Artemisia Abrotanum Flowering
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
多成分順勢療法複方: 無法完成老藥新用預測評估
One-Sentence Summary
This product is a multi-ingredient homeopathic combination containing 11 botanical, animal, and mineral components (including Arnica montana, Gelsemium sempervirens, Nitroglycerin/Gloninum, and Selenicereus grandiflorus), whose profile is consistent with a classical homeopathic cardiovascular/neuralgic remedy. The TxGNN model could not generate any predicted indication for this compound because no DrugBank ID was matched and no original approved indication was found. There is currently no clinical trial or published literature evidence that can be attributed to this specific formulation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record (no approved license found) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; in this case, not even a model prediction is available |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
TxGNN relies on a drug node anchored to a DrugBank ID and at least one approved indication to traverse the knowledge graph and score disease candidates. This compound has neither:
-
No DrugBank ID — The query string is a semicolon-delimited list of 11 raw ingredient names. None resolved to a single DrugBank entity. Without a node in the knowledge graph, neither the KG-path method nor the deep-learning model can propagate scores.
-
No original approved indication — The Taiwan (US) regulatory database returned zero licenses. Without a source disease anchor, the “From X to Y” repurposing frame cannot be constructed.
-
Homeopathic product complexity — Multi-ingredient homeopathic preparations are generally not represented as single entities in standard pharmacological databases (DrugBank, ChEMBL). Each ingredient would need to be evaluated individually, and ultra-dilute homeopathic preparations lack the receptor-binding or pharmacokinetic data required by TxGNN.
Because all three preconditions for a TxGNN evaluation are absent, the pipeline correctly returned an empty predicted_indications array. This is not a data pipeline error — it is an expected and valid result for this class of product.
US Market Information
No US NDA or approved license exists for this product.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No records found |
Safety Considerations
No structured safety data (warnings, contraindications, or drug-drug interactions) was retrieved from any source queried on 2026-03-24. Please refer to individual ingredient monographs and any available package insert for safety information.
Notable individual-ingredient flags for clinical awareness:
- Nitroglycerin (Gloninum in homeopathic nomenclature): At pharmacological doses, nitroglycerin is a potent vasodilator with well-characterised interactions with PDE-5 inhibitors (e.g., sildenafil) and antihypertensives. Whether the ultra-dilute homeopathic preparation carries the same risk profile is not established.
- Gelsemium sempervirens: The mother tincture contains strychnine-related alkaloids (gelsemine); toxicity at crude doses is documented. Homeopathic dilutions are generally regarded as non-toxic, but this should be confirmed per labelling.
Conclusion and Next Steps
Decision: Hold
Rationale: This product cannot be evaluated through the standard TxGNN repurposing pipeline because it lacks both a DrugBank node and an approved indication anchor. Proceeding without resolving these gaps would produce results with no scientific basis.
To proceed, the following is needed:
- Clarify the target compound — Determine whether the intent is to evaluate a specific single active ingredient (e.g., nitroglycerin alone) or the combination product as a whole. If a single active, resubmit with that INN and its DrugBank ID.
- Obtain a DrugBank ID — Map the intended active ingredient(s) to DrugBank entries so the TxGNN knowledge graph node can be identified.
- Confirm approved indication(s) — Identify at least one jurisdiction where this product (or the primary active) holds an approved indication to serve as the repurposing “source” disease.
- Decide on homeopathic scope — If the strategic interest is homeopathic product repurposing specifically, a separate evaluation framework outside TxGNN (e.g., systematic review of clinical evidence per individual ingredient) should be designed, as TxGNN is not validated for ultra-dilute preparations.
- Retrieve safety data — Once the active ingredient is clarified, pull TFDA package insert, DrugBank warnings, and DDI database entries to complete the S1 safety screening.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.